Literature DB >> 23935271

Twenty four-hour ambulatory blood pressure monitoring and lipid levels before, 3, 6 and 12 months after the onset of hemodialysis in chronic kidney disease patients: a pilot study.

Ag Vagiona1, Sa Koupidis, P Passadakis, El Thodis, V Vargemezis.   

Abstract

BACKGROUND: Twenty four-hour ambulatory blood pressure (BP) monitoring (ABPM) is being increasingly used to evaluate the effectiveness of antihypertensive medications. We aimed to to investigate the incidence of "non-dippers" in ESRD patients before, as well after the initiation of hemodialysis, to evaluate whether start of hemodialysis is associated with a reduction in the use of antihypertensive drugs, and to correlate 24-hour ABPM with serum lipid levels, the use of lipid-lowering drugs (statins) and the development of the Metabolic Syndrome (MetS) in these patients.
METHODS: Thirty patients scheduled to initiate hemodialysis (glomerular filtration rate <15 ml/min/1.73m(2)) were prospectively recruited. Twenty four-hour ABPM and lipid levels were recorded before (T0), as well as 3 (T1), 6 (T2) and 12 (T3) months after hemodialysis onset.
RESULTS: A progressively significant (p=0.025) decrease in the use of antihypertensive medications was observed in 26 of 30 patients throughout the study, whereas the remaining four patients were not hypertensive during the same period. There was a progressive increase in the use of statins for the management of dyslipidemia (p=0.015). This increase in statin use was coupled with an increase in the prevalence of the MetS in the study population (p=0.040). Patients with daily BP <135/85 mm Hg had a lower incidence of new MetS compared with patients with daily BP >135/85 mm Hg (p=0.053).
CONCLUSIONS: Patients initializing hemodialysis demonstrate a progressively increased incidence of dyslipidemia and MetS, as well as a reduction in the use of antihypertensive drugs. Optimal management of BP and dyslipidemias is essential to reduce the high cardiovascular morbidity and mortality rates in this high-risk population.

Entities:  

Keywords:  ambulatory blood pressure monitoring; dyslipidemia; hemodialysis; metabolic syndrome; statins

Year:  2012        PMID: 23935271      PMCID: PMC3738417     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  28 in total

1.  The epidemiology of systolic blood pressure and death risk in hemodialysis patients.

Authors:  Zhensheng Li; Eduardo Lacson; Edmund G Lowrie; Norma J Ofsthun; Martin K Kuhlmann; J Michael Lazarus; Nathan W Levin
Journal:  Am J Kidney Dis       Date:  2006-10       Impact factor: 8.860

Review 2.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

3.  Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates.

Authors:  Kosmas I Paraskevas; Alexandros A Tzovaras; Vassilios Stathopoulos; Dimitri P Mikhailidis
Journal:  Int Urol Nephrol       Date:  2010-01-01       Impact factor: 2.370

4.  Natural history of CKD stage 4 and 5 patients following referral to renal management clinic.

Authors:  Ai-Hua Zhang; Paul Tam; Denise LeBlanc; Hui Zhong; Christopher T Chan; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-07-04       Impact factor: 2.370

5.  Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic.

Authors:  Kosmas I Paraskevas; Nikolaos Bessias; Sotirios A Koupidis; Effie Tziviskou; Dimitri P Mikhailidis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12-18       Impact factor: 2.370

6.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

7.  Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study.

Authors:  Toshiharu Ninomiya; Yutaka Kiyohara; Yosuke Tokuda; Yasufumi Doi; Hisatomi Arima; Akiko Harada; Yasuo Ohashi; Hirotsugu Ueshima
Journal:  Circulation       Date:  2008-12-16       Impact factor: 29.690

8.  Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study.

Authors:  Yoshihiro Kokubo; Satoko Nakamura; Tomonori Okamura; Yasunao Yoshimasa; Hisashi Makino; Makoto Watanabe; Aya Higashiyama; Kei Kamide; Katsuyuki Kawanishi; Akira Okayama; Yuhei Kawano
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

Review 9.  Cardiovascular disease in chronic kidney disease.

Authors:  Anita M Saran; Thomas D DuBose
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-12

Review 10.  The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Authors:  Venkata Narla; Michael J Blaha; Roger S Blumenthal; Erin D Michos
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.